EGFR and central nervous system cancer: At the molecular level, O-6-methylguanine- DNA methyltransferase promoter methylation, EGFR alterations, IDHI or IDH2 mutation, and 1p19q codeletion are tested to diagnose gliomas (Rodriguez et al., 2016).